Tests a diet and exercise plan during chemotherapy for young people with leukemia
Tests a diet and exercise plan in young people with B-cell leukemia during chemotherapy.
Key facts
- Who runs it
- Etan Orgel
- Where
- Ann Arbor, Atlanta, Charlotte, Chicago, Cincinnati, Dallas, Denver, Houston, Kansas City, Los Angeles, Minneapolis, Orange, Philadelphia, Portland, Salt Lake City, and San Francisco, United StatesSee the 16 sites
- Trial code
- Registry title
- Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 240 people, planned
- Started
- 12 Mar 2022
- Expected to end
- 15 Aug 2032
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- IDEAL2 Intervention
- Record updated
- 19 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, teens and young adults with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) who are starting their first chemotherapy. It tests a calorie-restricted diet and exercise plan during the first month of chemotherapy.
- Age
- From 7.0 to under 26.0 years old.
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed B-ALL, with more than 25% blasts in the bone marrow or at least 1,000/µL leukemia cells in the blood, confirmed by flow cytometry.
- Earlier treatment
- This must be the first treatment attempt for B-ALL. The first chemotherapy phase must include vincristine, a glucocorticoid, pegaspargase/calaspargase, and daunorubicin or doxorubicin, and last less than 35 days. People who had treatment for an earlier cancer cannot join.
Main reasons for not taking part
- Underweight at enrolment
- Down syndrome or a DNA fragility syndrome such as Fanconi anemia or Bloom syndrome
- Pregnant
- Getting anti-CD20 antibody therapy during the first chemotherapy phase
- Cannot do the diet and exercise plan, for example because of severe developmental delay or paraplegia
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Patients must be ≥ 7.0 and <26.0 years of age
- Patients must have a diagnosis of de novo B-ALL
- Patients must have a M3 marrow (>25% blasts by morphology) or at least 1,000/µL circulating leukemia cells in PB confirmed by Flow Cytometry (or other convincing evidence of a B-ALL diagnosis not meeting above criteria following central review by the Study Hematopathologist and Study Chair or Vice-Chair)
- The treatment regimen must be the first treatment attempt for B-ALL-
- Must be a multi-agent induction regimen inclusive of vincristine, glucocorticoid, pegaspargase/calaspargase, and daunorubicin or doxorubicin and with a planned duration <35 days
- Organ function must meet that required for initiation of chemotherapy
- Patients at diagnosis must meet Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients ≤ 16 years of age (or be expected to recover prior to Day 8)
- If the patient is a female of childbearing potential, a negative urine or serum pregnancy test is required within two weeks prior to enrollment
Who cannot take part
- Patient receiving a SJCRH-style "Total Therapy" regimen will be excluded
- Patients receiving anti-CD20 monoclonal antibody therapy during induction therapy
- Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results
- Patients with Down syndrome or a DNA fragility syndrome (such as Fanconi anemia, Bloom syndrome) will be excluded
- Patients will be excluded if they received treatment for a previous malignancy
- Patient will be excluded if they are underweight at time of enrollment (BMI% <5th percentile for age for patients age 10-19 years, BMI <18.5 in patients 20-29 years)
- Patient will be excluded if they are pregnant
- Patient will be excluded if they have a pre-diagnosis requirement for enteral or parenteral supplementation
- Patient will be excluded due to inability to perform the intervention (e.g., specific nutritional needs, severe developmental delay, paraplegia)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 7 and 25 years old?
Where in United States
- C. S. Mott_University of MichiganAnn Arbor, United StatesContact: Jennifer Agrusa, M.D.Taking people
- Children's Healthcare of Atlanta at EglestonAtlanta, United StatesContact: Melinda Pauly, MD (principal investigator)Not yet recruiting
- Levine Children's HospitalCharlotte, United StatesContact: Joel Kaplan, DO (principal investigator)Taking people
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Jenna Rossoff, MD (principal investigator)Taking people
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Robin Norris, MDTaking people
- University of Texas, SouthwesternDallas, United StatesContact: Tamra Slone, MDTaking people
- Colorado Children's HospitalDenver, United StatesContact: Lisa Hartman, M.D.Taking people
- Baylor Texas Children's HospitalHouston, United StatesContact: Karen Rabin, M.D.Taking people
- Children's Mercy HospitalKansas City, United StatesContact: Keith August, MDTaking people
- Children's Hospital Los AngelesLos Angeles, United StatesContact: Etan Orgel, MD (principal investigator)Taking people
- Children's Hospitals and Clinics of MinnesotaMinneapolis, United StatesContact: Nathan Gossai, MD (principal investigator)Taking people
- Children's Hospital Orange CountyOrange, United StatesContact: Van Huynh, MD (principal investigator)Taking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Susan Rheingold, MD (principal investigator)Taking people
- Oregon Health Science UniversityPortland, United StatesContact: Bill Chang, MD (principal investigator)Taking people
- Primary Children's HospitalSalt Lake City, United StatesContact: Mallorie Heneghan, M.D.Taking people
- UCSF School of MedicineSan Francisco, United StatesContact: Michelle Hermiston, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even those who start chemotherapy at a healthy weight.
Read full original descriptionShow less
This study is being done to find out if caloric restriction achieved by a personalized nutritional menu and exercise plan during routine chemotherapy can make the patient's ALL more sensitive to chemotherapy and also reduce the amount of body fat gained during treatment. The goals of this study are to help make chemotherapy more effective in treating the patient's leukemia as demonstrated by fewer patients with leukemia minimal residual disease (MRD) while also trying to reduce the amount of body fat that chemotherapy causes the patient to gain in the first month.
The 2 groups in the trial
- IDEAL2 interventionTreatment being tested
Focused and short-term intervention of diet and exercise during induction. Calorie goal is \>=15% daily deficit as determined by each subject's estimated energy requirement. Fat intake will make up \<25% of daily calories. Carbohydrate will make up \<55% of daily calories consisting of "low" glycemic load foods (\<100/2,000 kcal adjusted for daily calories). Protein will make up \>=20% of daily calories. Subjects will also perform moderate exercise 5 days per week for 30 minutes/session (total = 150 minutes per week). Subjects will have a step goal to decrease sedentary behavior, with a starting goal of \>=1000 steps/day and increasing by at least 1000 steps/day each week.
- Control - Standard of CareNo study treatment, for comparison
One-time education of diet and exercise, which is the standard of care for ALL patients during induction.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Randomized Trial of Caloric Restriction and Activity to Reduce Chemoresistance in B-cell Acute Lymphoblastic Leukemia
- Plain-language title
- Tests a diet and exercise plan during chemotherapy for young people with leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05082519, who can take part
- Record updated
- 19 August 2026